Investor-ready IP strategy for a high-growth biotech startup
A fast-growing biotech startup with a novel diagnostic platform was preparing for a Series B round. Investors required clarity on…
Capability: Diligence-ready Materials
A defensible valuation range for an early-stage medtech company
An early-stage medtech company was preparing for a capital raise but lacked the revenue history a conventional valuation requires.